Company intelligence / Profile preview

TenX Acquisition

New York, United States

Ownership: Private
Development stage: Other

Overview

TenX Keane Acquisition, a former Special Purpose Acquisition Company (SPAC) focused on biotech and healthcare, merged on August 12, 2024, with Citius Pharmaceuticals' oncology subsidiary. This merger formed Citius Oncology, Inc., a biotech company specializing in oncology therapies, notably the FDA-approved immunotoxin LYMPHIR (denileukin diftitox-cxdl) for relapsed/refractory cutaneous T-cell lymphoma (CTCL).

Therapeutic areas: Oncology
Modalities: ImmunotoxinBiologic
Industry: Investors

Beyond the preview

Go deeper on TenX Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TenX Acquisition.

Explore the full profile